Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
기사 요약
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
신뢰할 수 있는 매체의 최신 소식을 간단한 요약과 함께 확인하세요. 자세한 내용은 원문 링크를 여세요.